Epidermal growth factor receptor dimerization interface (EGFR dimerization interface)

The human epidermal growth factor receptor (EGFR), also known as ErbB1 or HER1, is a transmembrane receptor tyrosine kinase involved in regulating cell proliferation and survival. Its extracellular domain binds ligands such as EGF or transforming growth factor-alpha. Ligand binding induces conformational changes leading to *dimerization*—either homodimers with another EGFR molecule or heterodimers with other family members like HER2/HER3/HER4. This *dimerization interface* on the extracellular module facilitates close apposition necessary for allosteric activation of intracellular kinase domains.\n\nActivation through this interface triggers autophosphorylation on specific cytoplasmic tail residues initiating multiple downstream signaling pathways controlling cell cycle progression and survival. Aberrant regulation at this site—through overexpression, mutation, or dysregulated multimer formation—is implicated heavily in oncogenesis across many cancers.\n\nRecent structural studies have elucidated how mutations at specific regions within Domain IV disrupt multivalent interactions required for higher-order oligomer formation beyond dimers. These findings highlight how cooperative interactions at the *dimerization interface* amplify signal output by promoting extensive phosphorylation events critical for robust cellular responses[1]. Understanding these molecular details informs therapeutic strategies aimed at disrupting pathological signaling mediated via this key functional site.\n\n---\n\nThis summary integrates molecular structure-function insights about the \"human epidermal growth factor receptor dimerization interface\" emphasizing its role as a validated therapeutic target primarily relevant in oncology contexts[1][2][3].

Other names

EGFR extracellular domain dimerization siteHER1 dimerization interfaceErbB1 dimerization region

Drugs targeting this molecule act mainly by: Preventing ligand-induced receptor dimerization/activation (monoclonal antibodies); Inhibiting tyrosine kinase catalytic activity post-dimerization (small molecule inhibitors)